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Abstract
IL-10 has been shown to block the antigen-specific T-cell
cytokine response by inhibiting the CD28 signaling pathway.
We found that peripheral blood CD4+ T cells from patients with
active rheumatoid arthritis (RA) were able to produce greater
amounts of interferon gamma after CD3 and CD28
costimulation in the presence of 1 ng/ml IL-10 than were normal
control CD4+ T cells, although their surface expression of the
type 1 IL-10 receptor was increased. The phosphorylation of
signal transducer and activator of transcription 3 was sustained
in both blood and synovial tissue CD4+ T cells of RA, but it was
not augmented by the presence of 1 ng/ml IL-10. Sera from RA
patients induced signal transducer and activator of transcription
3 phosphorylation in normal CD4+ T cells, which was mostly
abolished by neutralizing anti-IL-6 antibody. Preincubation of
normal CD4+ T cells with IL-6 reduced IL-10-mediated inhibition
of interferon gamma production. Blood CD4+ T cells from RA
patients contained higher levels of suppressor of cytokine
signaling 1 but lower levels of suppressor of cytokine signaling
3 mRNA compared with control CD4+ T cells, as determined by
real-time PCR. These results indicate that RA CD4+ T cells
become resistant to the immunosuppressive effect of IL-10
before migration into synovial tissue, and this impaired IL-10
signaling may be associated with sustained signal transducer
and activator of transcription 3 activation and suppressor of
cytokine signaling 1 induction.
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Introduction
IL-10 is a key cytokine in regulating inflammatory
responses, mainly by inhibiting the production and function
of proinflammatory cytokines. IL-10 binds to the IL-10
receptor (IL-10R) complex that is composed of two subu-
nits, the primary ligand-binding component type 1 IL-10R
(IL-10R1) and the accessory component type 2 IL-10R [1].
The interaction of IL-10 and IL-10R engages the Janus
kinase (JAK) family tyrosine kinases Jak1 and Tyk2, which
are constitutively associated with IL-10R1 and type 2 IL-
10R, respectively [2]. IL-10 induces tyrosine phosphoryla-
tion and activation of the latent transcriptional factors signal
transducer and activator of transcription (STAT) 3 and
STAT1 [3]. Upon phosphorylation, STAT1 and STAT3 pro-
teins form homodimers or heterodimers, rapidly translocate
into the nucleus, and modulate gene transcription. Intrigu-
ingly, STAT3 is indispensable for both IL-10-derived anti-
inflammatory and IL-6-derived proinflammatory responses
[4]. Studies of cell-type-specific STAT3-deficient mice
have shown that STAT3 activation is essential for IL-10-
mediated anti-inflammatory reactions in macrophages and
neutrophils [5], but is responsible for IL-6-mediated preven-
tion of apoptosis in T cells [6]. The suppressor of cytokine
signaling (SOCS) proteins have been identified as a family
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of endogenous JAK kinase inhibitors that can act in classic
feedback inhibition loops, but their roles as the mediators
of crosstalk inhibition by opposing cytokine signaling path-
ways have been clarified [7]. Recent studies indicate that
SOCS3 plays a key role in regulating the divergent action
of IL-10 and IL-6, by specifically blocking STAT3 activation
induced by IL-6 but not that induced by IL-10 [8,9].
The synovial membrane of rheumatoid arthritis (RA) is char-
acterized by an infiltrate of a variety of inflammatory cells,
such as lymphocytes, macrophages, and dendritic cells,
together with proliferation of synovial fibroblast-like cells.
Numerous cytokines are overproduced in the inflamed joint,
and macrophages and synovial fibroblasts are an important
source of proinflammatory cytokines. Tumor necrosis factor
alpha (TNF-α) and IL-1, two major macrophage products,
are crucial in the process of chronic inflammation and joint
destruction, and they give rise to effector components,
including other inflammatory cytokines, chemokines,
growth factors, matrix proteases, nitric oxide, and reactive
oxygen species [10]. IL-6 is a pleiotropic cytokine pro-
duced substantially by activated fibroblasts, and its proin-
flammatory actions include simulating the acute-phase
response, B-cell maturation into plasma cells, T-cell func-
tions, and hematopoietic precursor cell differentiation [11].
However, anti-inflammatory cytokines and cytokine inhibi-
tors are also present in large quantities in RA joints. IL-10,
produced by macrophages and partly by T cells in the syn-
ovial tissue (ST), is best known as a negative regulator for
macrophage and Th1 cells, but the expression level is insuf-
ficient to counterbalance the cascade of proinflammatory
events [12]. In addition, the anti-inflammatory action of IL-
10 appears to be modulated at the level of signal transduc-
tion during chronic inflammation. IL-10 signaling is impaired
in macrophages upon chronic exposure to proinflammatory
cytokines such as TNF-α and IL-1 and immune complexes
[13,14]. Cell surface expression of IL-10R1 is decreased in
synovial fluid dendritic cells due to the presence of TNF-α,
IL-1, and granulocyte–macrophage colony-stimulating fac-
tor [15].
CD4+ T cells may be activated by arthritogenic antigens, in
conjunction with CD28-mediated costimulatory signaling,
in RA. The significance of this autoimmune process has
been supported by the linkage of the MHC class II antigens
HLA-DRB1*0404 and HLA-DRB1*0401 with disease sus-
ceptibility and severity [16,17], and by the high-level
expression of MHC class II molecules and both CD28 lig-
ands, CD80 and CD86, in the inflamed ST [18-20]. The
continuing emergence of activated CD4+ T cells, even
though few in number, may be crucial in sustaining the acti-
vation of macrophages and synovial fibroblasts through cell
surface signaling by means of cell surface CD69 and
CD11, as well as the release of proinflammatory Th1
cytokines such as interferon gamma (IFN)-γ and IL-17
[21,22]. In addition, CD4+ T cells could stimulate B-cell
production of autoantibodies such as rheumatoid factor
and osteoclast-mediated bone destruction. Their obligatory
role in RA synovitis was recently proved by successful
treatment of active disease by selective inhibition of T-cell
activation with fusion protein of cytotoxic T-cell-associated
antigen 4 (CD152)-IgG, which can block the engagement
of CD28 on T cells by binding to CD80 and CD86 with
high avidity [23].
IL-10 efficiently blocks the antigen-specific T-cell cytokine
response by inhibiting the CD28 signaling pathway [24], as
well as indirectly by downregulating the function of antigen-
presenting cells. To elucidate the resistance of CD4+ T
cells to this direct inhibition in RA, we investigated the pro-
duction of IFN-γ after CD3 and CD28 costimulation in the
presence of IL-10, the induction of STAT1 and STAT3
phosphorylation by IL-10, and the expression of SOCS1
and SOCS3 mRNA in peripheral blood (PB) CD4+ T cells
from RA patients.
Materials and methods
Patients and samples
The total patient population consisted of 32 patients with
RA (25 women and seven men; mean ± standard deviation
age, 52.8 ± 12.4 years) diagnosed according to the
revised 1987 criteria of the American College of Rheuma-
tology (formally, the American Rheumatism Association)
[25]. All patients were receiving prednisolone (≤ 7.5 mg/
day) and disease-modifying antirheumatic drugs. Clinical
parameters in the study patients were as follows (mean ±
standard deviation): erythrocyte sedimentation rate, 55.9 ±
35.4 mm/hour; serum C-reactive protein (CRP) level, 32.0
± 32.0 mg/l; and IgM class rheumatoid factor titer, 142 ±
158 U/ml. Patients were divided into two groups: 24
patients with active disease, who had multiple tender and/
or swollen joints and elevated serum CRP level (≥ 10 mg/
l); and eight patients with inactive disease, who satisfied
the American College of Rheumatology preliminary criteria
for clinical remission [26]. Sixteen healthy volunteers (11
women and five men; age, 45.8 ± 11.2 years) served as
controls. ST samples were obtained from three RA patients
undergoing total knee replacement. All patients gave
informed consent.
Isolation of CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were pre-
pared from heparinized blood samples by centrifugation
over Ficoll-Hypaque density gradients (Pharmacia, Upp-
sala, Sweden). CD4+ T cells were purified from PBMC by
positive selection using anti-CD4 mAb-coated magnetic
beads (Miltenyi Biotec, Gladbach, Germany), according to
the manufacturer's instructions. CD4+ T cells were isolated
from ST samples, as previously described [27]. Briefly,Available online http://arthritis-research.com/content/6/6/R567
R569
fresh ST samples were fragmented and digested with col-
lagenase and DNase for 1 hour at 37°C. After removing tis-
sue debris, ST cell suspensions in culture medium (RPMI
1640 medium; Life Technologies, Gaithersburg, MD, USA)
supplemented with 25 mM HEPES (2 mM L-glutamine, 2%
nonessential amino acids, 100 IU/ml penicillin, and 100
mg/ml streptomycin; Life Technologies) with 10% heat-
inactivated FCS (Life Technologies) were incubated at
37°C in six-well plates (Coster, Cambridge, MA, USA) for
45 min. Non-adherent cells were harvested and CD4+ T
cells were purified by positive selection as already
described.
Culture of CD4+ T cells
PB CD4+ T-cell populations were resuspended at a density
of 1 × 106 cells/ml in culture medium with 10% FCS, and
0.5 ml cell suspensions were dispensed into the wells of
24-well microtiter plates (Coster) coated with 1 µg/ml anti-
CD3 mAb (Immunotech, Marseille, France). The cells were
incubated with 1 µg/ml anti-CD28 mAb (Immunotech) in
the presence or absence of the indicated concentrations of
IL-10 (Becton Dickinson, San Jose, CA, USA) at 37°C in a
humidified atmosphere containing 5% CO2 [28]. Culture
supernatants were collected 36 hours later and cell-free
samples were stored at -30°C until cytokine assay.
To examine the effect of IL-6 on T-cell responsiveness to IL-
10, CD4+ T cells from healthy controls were incubated in
culture medium with 10% FCS in the presence or absence
of 10 ng/ml IL-6 (Becton Dickinson) for 36 hours. Cells
were then stimulated for 36 hours with anti-CD3 mAb and
anti-CD28 mAb in the presence or absence of 1 ng/ml IL-
10. Culture supernatants were measured for IFN-γ
concentrations.
Flow cytometric analysis for IL-10R1 expression
A sample of 5 × 105 cells of PBMC was resuspended in
PBS with 1% FCS. PBMC were incubated with saturating
concentrations of anti-IL-10R1 mAb (IgG1; R&D systems,
Minneapolis, MN, USA) or with isotype-matched control
mAb (Immunotech), followed by incubation with FITC-con-
jugated goat anti-mouse IgG1 polyclonal antibody (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA). Cells were
then incubated with phycoerythrin-conjugated anti-CD4
mAb (Becton Dickinson). Cells were washed well with 1%
FCS/PBS between incubations. Analysis was performed
on a FACScan flow cytometer (Becton Dickinson).
Immunoassay for IFN-γ and IL-2
Concentrations of IFN-γ and IL-2 in culture supernatants of
CD4+ T cells were measured in duplicate by the quantita-
tive sandwich ELISA using cytokine-specific capture with
biotinylated detection mAb and recombinant cytokine pro-
teins (all from Becton Dickinson), according to the manu-
facturer's protocol. The detection limits for IFN-γ and IL-2
were 15 pg/ml.
Isolation of mRNA and real-time PCR
Total cellular RNA was extracted from PB CD4+ T cells
using an RNA isolation kit (RNeasy Mini kit; Qiagen, Valen-
cia, CA, USA), according to the manufacturer's instruc-
tions. cDNA was synthesized from total RNA with Molony
murine leukemia virus reverse transcriptase (US Biochemi-
cal, Cleveland, OH, USA) and oligo-(dT)15  primers
(Promega, Madison, WI, USA). Real-time PCR was per-
formed with the LightCycler Instrument (Roche Diagnos-
tics, Penzberg, Germany) in glass capillaries. The reaction
mix containing Taq DNA polymerase and DNA double-
strand-specific SYBR Green I dye (Lightcycler FastStart
DNA Master SYBR Green I; Roche Diagnostics) and spe-
cific primers were added to cDNA dilutions.
The cDNA samples were denatured at 95° C for 10 min,
and were then amplified for 40–50 cycles: at 95° C (10 s),
at 65° C (15 s), and 72° C (22 s) for β-actin; at 95° C (10
s), at 62° C (15 s), and at 72° C (10 s) for SOCS1; and at
96° C (10 s), at 68° C (15 s), and at 72° C (15 s) for
SOCS3. Amplification curves of the fluorescence values
versus cycle number were obtained, and a melting curve
analysis was then performed. The levels of SOCS1 and
SOCS3 expression were determined by normalizing rela-
tive to β-actin expression. The forward and reverse primers
were as follows: for β-actin, 5'-GTGGGGCGCCCCAGG-
CACCA-3' and 5'-CTCCTTAATGTCACGCACGATTTC-
3' ; for SOCS1, 5'-AGACCCCTTCTCACCTCTTG-3' and
5'-GCACAGCAGAAAAATAAAGC-3' ; and for SOCS3,
5'-CCCGCCGGCACCTTTCTG-3' and 5'-AGGGGCCG-
GCTCAACACC-3'.
Western blot analysis
CD4+ T cells were stimulated for 20 min by the indicated
concentrations of IL-10 and IL-6 at a density of 5 × 105
cells in 0.5 ml culture medium with 10% FCS. To examine
the effect of serum IL-6 on STAT phosphorylation, normal
CD4+ T cells were stimulated for 20 min with 30% active
RA serum in culture medium with 40 µg/ml neutralizing
goat anti-IL-6 polyclonal antibody (IgG; Techne, Princeton,
NJ, USA) or control goat IgG (Techne). Whole cell lysates
were prepared by placing cells in 100 µl SDS lysing buffer
(62.5 mM Tris–HCl [pH 6.8], 2% SDS, 10% glycerol, 50
mM dithiothreitol, 0.1% bromphenol blue). Then 20 µl pro-
tein samples were fractionated on 10% SDS-polyacryla-
mide gels and were transferred to nitrocellulose
membranes (Amersham, Buckinghamshire, UK), and the
membrane was blocked with 5% skim milk in Tris-buffered
saline with 0.1% Tween 20.
Tyrosine phosphorylation of STAT1 and STAT3 was
detected using commercial available kits (Cell SignalingArthritis Research & Therapy    Vol 6 No 6    Yamana et al.
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Technology, Beverly, MA, USA) according to the manufac-
turer's instructions. Briefly, the membrane was incubated
with the antibodies (rabbit IgG) anti-STAT1 antibody, anti-
phosphorylated tyrosine 701 of STAT1 antibody, anti-
STAT3 antibody, and anti-phosphorylated tyrosine 705 of
STAT3 antibody, diluted as recommended at 1/2000 with
Tris-buffered saline with 0.1% Tween 20 with 5% BSA.
Antibody binding was detected by horseradish peroxidase-
conjugated anti-rabbit IgG antibody diluted at 1/4000 with
Tris-buffered saline with 0.1% Tween 20 with 5% BSA,
and was revealed using the chemiluminescence system.
Protein bands were quantified by densitometry using NIH-
Image analysis, and STAT phosphorylation was compared
with the total amount of STAT protein. IFN-γ-stimulated
Hela cells were used as a positive control for STAT1
phosophorylation.
Statistical analysis
Data are expressed as the mean value ± standard error of
the mean or box plots. The statistical significance of differ-
ences between two groups was determined by the Mann–
Whitney U test or the Wilcoxon signed rank test. P < 0.05
was considered significant.
Results
Resistance to IL-10 inhibition of IFN-γ production in RA 
CD4+ T cells
The CD28 costimulatory pathway is crucial for effective
antigen-specific T-cell cytokine production, and IL-10 can
directly suppress this response by inhibiting CD28 tyrosine
phosphorylation and binding of phosphatidylinositol 3-
kinase [24]. To evaluate the responsiveness of RA CD4+ T
cells to IL-10, purified PB CD4+ T cells from three patients
with active RA and from three healthy controls were stimu-
lated by immobilized anti-CD3 antibody and anti-CD28
antibody with or without diluted concentrations of IL-10 for
36 hours, and IFN-γ production was measured by ELISA.
As shown in Fig. 1, IFN-γ production by activated normal
CD4+ T cells was mostly inhibited at concentrations as low
as 1 ng/ml IL-10. However, RA CD4+ T cells were able to
produce significant amounts of IFN-γ in the presence of 1
ng/ml IL-10, and the maximal but not complete inhibition by
IL-10 was obtained at 10–100 ng/ml.
We thus compared the levels of IFN-γ production by CD4+
T cells after CD3 and CD28 costimulation in the presence
of 1 ng/ml IL-10 in RA patients with active disease (multiple
inflammatory joints, CRP level ≥ 10 mg/l) and inactive dis-
ease (in remission, CRP level < 10 mg/l) [26] and in healthy
controls. There were no statistically significant differences
in IFN-γ production without IL-10 among these three
groups (Fig. 2a), but the inhibitory effect of IL-10 on IFN-γ
production was significantly limited in the active RA group
as compared with the inactive RA group and healthy con-
trols (percentage decrease: active RA, 2.9 ± 14.4%; inac-
tive RA, 45.6 ± 14.4%; controls, 65.8 ± 7.9%) (Fig. 2b). As
a consequence, CD4+ T cells from active RA patients pro-
duced higher levels of IFN-γ in the presence of 1 ng/ml IL-
10 than did normal CD4+ T cells (Fig. 2a).
In addition, we compared IL-2 production by CD4+ T cells
after CD3 and CD28 costimulation in the presence of IL-10
in active RA patients and in healthy controls. Similarly, IL-2
production was not affected by 1 ng/ml IL-10 in RA
patients (percentage decrease, -2.1 ± 13.8%), while it was
significantly reduced in healthy controls (61.1 ± 13.7%; P
< 0.05). Taken together, these results indicate that RA
CD4+ T cells become less susceptible to the immunoregu-
latory effect of IL-10 during the active phase.
Increased expression of cell surface IL-10R1 on RA CD4+ 
T cells
The functional receptor complex of IL-10 consists of two
subunits, the primary ligand-binding component IL-10R1
and the accessory component type 2 IL-10R [1]. IL-10R1
expression plays a critical role in cellular responses to IL-10
[29]. To examine whether the resistance to IL-10 inhibition
in RA CD4+ T cells was due to limited receptor expression,
the cell surface expression of IL-10R1 on PB CD4+ T cells
Figure 1
Dose response of IL-10 inhibition of interferon gamma (IFN-γ) produc- tion by CD4+ T cells after CD3 and CD28 costimulation in patients with  rheumatoid arthritis (RA) and in healthy controls (HC) Dose response of IL-10 inhibition of interferon gamma (IFN-γ) produc-
tion by CD4+ T cells after CD3 and CD28 costimulation in patients with 
rheumatoid arthritis (RA) and in healthy controls (HC). CD4+ T cells 
were purified from peripheral blood mononuclear cells of three RA 
patients and three HC by positive selection with anti-CD4 antibody. 
CD4+ T cells (5 × 105 cells in 0.5 ml culture medium with 10% FCS) 
were stimulated by immobilized anti-CD3 antibody and anti-CD28 anti-
body in the presence or absence of diluted IL-10 concentrations for 36 
hours. Culture supernatants were measured for concentrations of IFN-γ 
by ELISA. IFN-γ production with IL-10 expressed as % IFN-γ production 
without IL-10. Values are the mean ± standard error of the mean.
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from active RA patients and from healthy controls was
determined by flow cytometric analysis. As shown in Fig.
3a,3b, the intensity of IL-10R1 expression on CD4+ T cells
was significantly increased in RA patients compared with in
healthy controls. These results suggest that the intracellular
signal transduction pathway of IL-10 may be impaired in
CD4+ T cells of active RA.
Defective IL-10-mediated STAT3 phosphorylation in RA 
CD4+ T cells
The interaction of IL-10R with IL-10 induces tyrosine phos-
phorylation and activation of the latent transcription factors
Figure 2
(a) Interferon gamma (IFN-γ) production by CD3 and CD28 costimu- lated CD4+ T cells in the presence of IL-10 in patients with rheumatoid  arthritis (RA) and in healthy controls (HC) (a) Interferon gamma (IFN-γ) production by CD3 and CD28 costimu-
lated CD4+ T cells in the presence of IL-10 in patients with rheumatoid 
arthritis (RA) and in healthy controls (HC). CD4+ T cells (5 × 105 cells 
in 0.5 ml culture medium with 10% FCS) were stimulated by anti-CD3 
antibody and anti-CD28 antibody with or without 1 ng/ml IL-10. Con-
centrations of IFN-γ in culture supernatants were measured in duplicate 
by ELISA. RA patients were divided into those with active disease (mul-
tiple inflammatory joints and CRP level ≥ 10 mg/l) and inactive disease 
(in remission and CRP level ≤ 4 mg/l). The results are represented as a 
box plot; upper and lower bars, 90th and 10th percentiles, respectively; 
upper, center and lower lines of box, 75th, 50th, and 25th percentiles, 
respectively. (b) Percentage of IFN-γ production. IFN-γ production with 
IL-10 expressed as % IFN-γ production without IL-10. Values are the 
mean ± standard error of the mean. n, number of samples tested.
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(a) Cell surface expression of type 1 interleukin-10 receptor (IL-10R1)  on CD4+ T cells from patients with rheumatoid arthritis (RA) and from  healthy controls (HC) (a) Cell surface expression of type 1 interleukin-10 receptor (IL-10R1) 
on CD4+ T cells from patients with rheumatoid arthritis (RA) and from 
healthy controls (HC). Peripheral blood mononuclear cells were stained 
with anti-IL-10R1 antibody or with isotype-matched control antibody, 
followed by incubation with FITC-conjugated goat anti-mouse IgG1 pol-
yclonal antibody, and were then stained with phycoerythrin-conjugated 
anti-CD4 mAb. The expression of CD4 and IL-10R1 was determined by 
flow cytometric analysis. Representative histographic patterns of IL-
10R1 expression on CD4+ T cells from RA patients and HC are shown. 
(b) The intensity of IL-10R1 on CD4+ T cells was expressed as the ratio 
of the mean fluorescence intensity (MFI) of staining with anti-IL-10R1 to 
control antibody. Values are the mean ± standard error of the mean. n, 
number of samples tested.
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STAT1 and STAT3 [3]. Macrophage-specific STAT3-defi-
cient mice demonstrated that STAT3 plays a dominant role
in IL-10-mediated anti-inflammatory responses [5], which
has recently been confirmed in human macrophages by
studies of dominant-negative STAT3 overexpression [30].
The induction of STAT1 and STAT3 phosphorylation by IL-
10 in PB CD4+ T cells from active RA patients and from
healthy controls was examined using western blotting.
STAT3 phosphorylation was dose-dependently induced
after IL-10 activation for 20 min in normal CD4+ T cells (Fig.
4a,4b). In contrast, STAT3 was phosphorylated in freshly
isolated PB CD4+ cells from RA patients and this STAT3
phosphorylation was detectable for up to 6 hours. STAT3
phosphorylation was augmented only when activated by as
much as 10 ng/ml IL-10. Both sustained STAT3 phospho-
rylation and defective IL-10-induced STAT3 phosphoryla-
tion were found in RA ST CD4+ T cells (Fig. 4c). On the
other hand, IL-10-induced STAT1 phosphorylation was not
detected in either RA CD4+ T cells or normal CD4+ T cells
(Fig. 4a). These results indicate that STAT3 is the major IL-
10-activated STAT in CD4+ T cells, and IL-10-induced
STAT3 activation may be diminished in active RA, in asso-
ciation with sustained STAT3 phosphorylation.
IL-6-mediated STAT3 phosphorylation and inhibition of 
IL-10 effect in normal CD4+ T cells
STAT3 is activated by many cytokines and growth factors
such as the IL-6 family of cytokines (IL-6, IL-11, leukemia
inhibitory factor, and oncostatin M), platelet-derived growth
factor, and epidermal growth factor, in addition to IL-10 [4],
but previous studies have demonstrated that IL-6 is the
major factor in RA synovial fluid that induces constitutive
activation of STAT3 in mononuclear cells [31]. Since IL-6 is
also abundant in sera of active RA patients, frequently
detected at > 1 ng/ml [27], we examined whether persist-
ent exposure of CD4+ T cells to high concentrations of IL-
6 in the blood circulation was responsible for their sus-
tained STAT3 activation and resistance to IL-10 inhibition
in active RA. Both STAT1 and STAT3 phosphorylation was
activated by IL-6 in normal CD4+ T cells (data not shown),
in agreement with previous observations [4]. Normal CD4+
T cells were thus incubated for 20 min with culture medium
containing 30% serum from active RA patients and neutral-
izing anti-IL-6 antibody or control antibody, and STAT phos-
phorylation was examined by western blot analysis. RA
serum was able to induce tyrosine phosphorylation of
STAT3 but not STAT1, and this STAT3 activation was
mostly abolished by neutralization of IL-6 activity (Fig. 5a).
These results indicate that IL-6 is the dominant STAT3-acti-
vating factor contained in sera of active RA patients. The
lack of STAT1 activation by RA serum suggests that much
higher concentrations of IL-6 may be required for STAT1
activation as compared with STAT3 activation, or that inhib-
itors of STAT1 signaling may be present in RA serum.
We next examined whether IL-6 could suppress the effect
of IL-10 to inhibit IFN-γ production by CD4+ T cells. After
preincubation with or without 10 ng/ml IL-6 for 36 hours,
normal CD4+ T cells were stimulated by CD3 and CD28
costimulation in the presence or absence of 1 ng/ml IL-10
for 36 hours, and the IFN-γ production was measured by
ELISA. IL-6 pretreatment of normal cells reduced IL-10-
mediated inhibition of IFN-γ production (Fig. 5b), indicating
Figure 4
(a) IL-10-mediated phosphorylation of signal transducer and activator  of transcription (STAT) 1 and STAT3 in CD4+ T cells from patients with  rheumatoid arthritis (RA) and from healthy controls (HC) (a) IL-10-mediated phosphorylation of signal transducer and activator 
of transcription (STAT) 1 and STAT3 in CD4+ T cells from patients with 
rheumatoid arthritis (RA) and from healthy controls (HC). CD4+ T cells 
(5 × 105 cells in 0.5 ml culture medium with 10% FCS) were incubated 
with or without IL-10 (1 and 10 ng/ml) and cells were harvested 20 min 
later. Whole cell extracts were prepared by placing cells in SDS buffer, 
and tyrosine phosophorylation (p-Tyr) of STAT1 and STAT3 was 
detected by western blot analysis. IFN-γ-stimulated Hela cells were 
used as a positive control for STAT1 phosphorylation. (b) Percentage 
of IL-10-activated STAT3 phosphorylation in CD4+ T cells from RA 
patients and from HC. Protein bands were quantified by densitometry 
using NIH-Image analysis, and STAT3 phosphorylation was expressed 
as % total STAT3 protein. (c) STAT3 phosphorylation in ST CD4+ T 
cells from RA patients. Representative results of STAT3 phosphoryla-
tion in CD4+ T cells from three synovial tissue samples of RA patients 
and three peripheral blood samples of HC are shown. Values are the 
mean ± standard error of the mean. n, number of samples tested.
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that high concentrations of IL-6 could modulate T-cell
responsiveness to IL-10. Taken together, these findings
suggest that persistent exposure to serum IL-6 may have a
role in both the induction of STAT3 activation and the
resistance to the inhibitory effect of IL-10 in RA CD4+ T
cells.
High expression of SOCS1 mRNA in RA CD4+ T cells
IL-6 induces two potent inhibitors of JAKs (SOCS1 and
SOCS3 proteins) that not only act as mediators of negative
feedback inhibition, but also play a major role in crosstalk
inhibition by opposing other cytokine-signaling pathways
[7]. SOCS3 has recently been shown to specifically inhibit
STAT3 activation induced by IL-6 but not by IL-10, thereby
regulating the divergent action of IL-6 and IL-10 [8,9]. On
the contrary, SOCS1 is able to partially inhibit IL-10-medi-
ated STAT3 activation and cellular responses, as well as
IFN-γ-mediated STAT1 activation [32]. To determine
whether SOCSs were involved in the defective IL-10-
induced STAT3 activation of RA CD4+ T cells, the levels of
SOCS1 and SOCS3 mRNA expression in PB CD4+ T cells
from active RA patients and from healthy controls were
compared by semiquantitative real-time PCR. The RA
CD4+ T cells contained higher levels of SOCS1 but lower
levels of SOCS3 transcripts than did control CD4+ T cells
(Fig. 6a). Constitutive expression of SOCS1 mRNA in RA
CD4+ T cells was comparable with the expression in normal
CD4+ T cells stimulated by 10 ng/ml IL-6 (Fig. 6b), support-
ing its functional significance. Defective IL-10-induced
STAT3 activation therefore appears to be due at least in
part to an abundance of SOCS1 in RA CD4+ T cells.
Discussion
CD4+  T cells orchestrate the Th1-type cell-mediated
immune response in RA [22]. Activated CD4+ T cells stim-
ulate macrophages, synovial fibroblasts, B cells, and oste-
oclasts through the expression of cell surface molecules
and Th1 cytokines, thereby contributing to both the chronic
inflammation and the joint destruction. CD4+ T cells require
two signals to be activated; antigen receptor occupancy
and CD28-mediated costimulation. In the ST lesion, the
CD28 ligands, both CD80 and CD86, together with MHC
class II antigens, are substantially expressed by antigen-
presenting cells such as macrophages and dendritic cells
[18-20]. The significance of CD28 engagement in the T-
cell-mediated disease process has recently been proven by
the clinical efficacy of its blocker cytotoxic T-cell-associ-
ated antigen 4 (CD152)-IgG in RA patients [23].
IL-10 plays a predominant role in limiting immune and
inflammatory responses by regulating the function of both
macrophages and Th1 cells [1]. IL-10 inhibits the tyrosine
phosphorylation of the CD28 molecule and the subsequent
phosphatidylinositol 3-kinase binding in T cells, and
thereby directly acts on T cells [24]. In the present study,
we found that PB CD4+ T cells from patients with active
RA, in the presence of IL-10, are able to produce higher lev-
els of IFN-γ after CD3 and CD28 costimulation than normal
CD4+ T cells. Despite high-level IL-10R1 expression and
constitutive STAT3 activation, IL-10-induced tyrosine
phosphorylation of STAT3 is suppressed in RA CD4+ T
cells, in contrast to normal CD4+ T cells, where STAT3
phosphorylation is dose-dependently inducible by IL-10.
Serum IL-6 from RA patients induces STAT3 but not
STAT1 phosphorylation in normal CD4+ T cells, and exog-
Figure 5
(a) Activation of signal transducer and activator of transcription (STAT)  3 in normal CD4+ T cells by serum IL-6 from patients with rheumatoid  arthritis (RA) (a) Activation of signal transducer and activator of transcription (STAT) 
3 in normal CD4+ T cells by serum IL-6 from patients with rheumatoid 
arthritis (RA). CD4+ T cells from healthy controls (5 × 105 cells in 0.5 ml 
culture medium) were stimulated by 30% RA serum in the presence of 
neutralizing anti-IL-6 antibody (Ab) (40 µg/ml) or of control antibody (40 
µg/ml) for 20 min. Phosophorylation of STAT1 and STAT3 was 
detected by western blot analysis.(b) Effect of IL-6 pretreatment on IL-
10 inhibition of IFN-γ production by CD4+ T cells. CD4+ T cells (5 × 
105 cells in 0.5 ml culture medium with 10% FCS) were incubated with 
or without IL-6 (10 ng/ml) for 36 hours, and were then stimulated by 
anti-CD3 antibody and anti-CD28 antibody in the presence or absence 
of IL-10 (1 ng/ml) for 36 hours. Concentrations of IFN-γ in culture 
supernatants were measured in duplicate by ELISA. IFN-γ production 
with IL-10 was expressed as % IFN-γ production without IL-10. Values 
are the mean ± standard error of the mean. n, number of samples 
tested. P-Tyr, tyrosine phosophorylation.
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enous IL-6 induces the resistance to IL-10 inhibition of IFN-
γ production. RA CD4+ T cells contain higher levels of
SOCS1 but contain lower levels of SOCS3 transcripts in
comparison with normal CD4+ T cells. These findings indi-
cate that CD4+ T cells become resistant to the inhibitory
effect of IL-10 before migration into the inflamed ST, and
suggest that this resistance may be attributable to impaired
IL-10-dependent STAT3 activation, in association with sus-
tained STAT3 phosphorylation and SOCS1 induction.
IL-10-mediated inhibition of CD4+ T-cell cytokine produc-
tion is principally dependent on its inhibition of macrophage
antigen-presenting cell function [1]. However, this indirect
inhibitory effect is thought to be restricted at the site of T-
cell activation in RA, because macrophages in the ST
express high levels of cytokines, CD80 and CD86
molecules, and MHC class II antigens [10,18-20]. More
recently, IL-10 has been shown to induce the antigen-spe-
cific T-cell unresponsiveness by inhibiting CD28 tyrosine
phosphorylation [33]. This direct effect also may be limited
in active RA patients, because their PB CD4+ T cells
showed a defective IL-10 inhibition of CD28-costimulated
production of both IFN-γ and IL-2.
Numerous cytokines, both proinflammatory and anti-inflam-
matory, have been detected in the ST of RA, and the bal-
ance between these opposing cytokine activities regulates
disease severity [10]. Endogenous IL-10, produced mainly
by macrophages and T cells, inhibits proinflammatory
cytokine production by ST cells [12]. However, this regula-
tory activity seems to be restricted during chronic inflamma-
tion. The activation of both the extracellular stimulus-
regulated kinase and p38 kinase pathways, induced by
TNF-α and IL-1, inhibits the Jak1–STAT3 signaling pathway
shared by IL-10 and IL-6 in adhered macrophages [13].
More importantly, IL-10-mediated STAT3 activation is
mostly undetectable in RA synovial macrophages. This
impaired IL-10 signaling is probably induced by chronic
exposure to immune complexes in vivo, because both cell
surface IL-10R1 expression and IL-10-induced Jak1 activa-
tion are suppressed in IFN-γ-primed macrophages by a pro-
tein kinase C-dependent pathway following ligation of the
IgG Fc gamma receptor [14]. Furthermore, dendritic cells
from RA synovial fluids are resistant to the immunoregula-
tory effect of IL-10 due to decreased transport of intracel-
lular IL-10R1 in the presence of proinflammatory cytokine
stimuli such as TNF-α, IL-1, and granulocyte–macrophage
colony-stimulating factor [15]. We have demonstrated that
the resistance of RA CD4+ T cells to IL-10 may be associ-
ated with defective IL-10-dependent STAT3 activation, but
not with IL-10R1 expression. Inhibitory effects of IL-10 on
these inflammatory cell types are therefore differentially
modulated at the signal transduction level under the inflam-
matory environment in RA.
In association with impaired IL-10-mediated STAT3 activa-
tion, STAT3 was found to be tyrosine phosphorylated per-
sistently (up to 6 hours) in freshly isolated PB and ST CD4+
T cells from RA patients. STAT3 is activated by a variety of
cytokines, notably the IL-6 family of cytokines (e.g. IL-6, IL-
11, leukemia inhibitory factor, and oncostatin M) and
growth factors, in addition to IL-10 [4]. Of these cytokines,
IL-6 plays a predominant role in eliciting a systemic reaction
such as the acute phase response in active RA, due mainly
to its abundance in the blood circulation [27]. Consistent
Figure 6
(a) The mRNA expression of SOCS1 and SOCS3 in CD4+ T cells from  patients with RA and healthy controls (HC) (a) The mRNA expression of SOCS1 and SOCS3 in CD4+ T cells from 
patients with RA and healthy controls (HC). Total cellular RNA was 
extracted from freshly isolated CD4+ T cells and mRNA expression of 
SOCS1 and SOCS3 was analyzed by real time-PCR as described in 
Patients and Methods. Levels of SOCS1 and SOCS3 mRNAs were 
normalized relative to β-actin expression. Values are the mean ± SEM. n 
= number of samples tested. (b) Kinetics of IL-6-induced SOCS1 
mRNA expression in normal CD4+ T cells. CD4+ T cells from HC (5 × 
105 cells in 0.5 ml of culture medium with 10% FCS) were stimulated 
with IL-6 (10 ng/ml) and SOCS1 mRNA expression was determined at 
the indicated time after stimulation.
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with this notion, IL-6 was the major STAT3-activating factor
contained in the serum of active RA patients, and the
responsiveness to IL-10 was suppressed in normal CD4+ T
cells after 36 hours of incubation with IL-6. These results
suggest that both the sustained STAT3 activation and the
resistance to IL-10 inhibition found in RA CD4+ T cells may
be induced after chronic exposure in vivo to high concen-
trations of serum IL-6. However, it is also possible that
STAT3 activity could be constitutively induced in CD4+ T
cells by their own IL-10 secretion, leading to the loss of
sensitivity to exogenous IL-10, because RA CD4+ T cells in
the ST are capable of producing significant levels of IL-10
[34].
CD4+ T cells isolated from the ST of RA also showed a
defect in the IL-10-induced STAT3 signaling pathway. It is
most probable that the resistance of CD4+ T cells to IL-10
can be even augmented after migration into the inflamed
ST, because IL-6 is highly concentrated compared with the
blood level [27]. In addition, the involvement of other essen-
tial proinflammatory cytokines in this process was sug-
gested by our preliminary experiments demonstrating that
IL-10-mediated IFN-γ inhibition in CD4+  T cells was
reduced by pretreatment with IL-1β and TNF-α, although
less effectively than by IL-6 (data not shown). Furthermore,
IFN-γ and IL-10 produced by CD4+ T cells themselves
could be responsible for impaired IL-10 signaling in the ST,
because T-cell infiltrates produce both cytokines [34,35].
In an autocrine fashion, IL-10 may persistently stimulate
STAT3 activation and IFN-γ can induce SOCS1 protein as
a crosstalk inhibitor of IL-10 signaling [32]. The T-cell-inhib-
itory effect of IL-10 may therefore be modulated complicat-
edly upon exposure to an inflammatory environment in RA
joints, where many cytokines are present substantially [10].
STAT3 activation has been implicated in the pathogenesis
of RA. Active STAT3 is constitutively expressed in synovial
fluid mononuclear cells from RA patients [36]. IL-6 is the
major STAT3-activating factor present in synovial fluid,
which has a crucial role in the activation of monocyte func-
tions such as gene expression of the Fc gamma receptor
type I and type III and of HLA-DR [31]. More recently, high
levels of activated STAT3, thought to be induced mainly by
IL-6, have been detected in the ST, and STAT3 activation
has been shown to be involved in synovial fibroblast prolif-
eration and IL-6 production [37]. In this regard, STAT3 is
critical in the survival and expansion of growth factor-
dependent synovial fibroblasts [38]. Furthermore, the
significance of persistent STAT3 signaling in Th1-cell-dom-
inated autoimmune arthritis has been suggested by studies
of the gp130F759/F759 mice, in which the Src homology
phosphatase-2 binding site of gp130 (the transmembrane
glycoprotein β subunit of the IL-6 family cytokine receptor),
tyrosine 759, was mutated to phenylalanine [39]. In the
gp130F759/F759 mice, T cells, particularly the CD4+ T-cell
subset, are chronically activated and resistant to activation-
induced cell death through gp130-mediated STAT3
activation.
The longevity of cytokine signals transduced by the JAK–
STAT pathway is regulated by the SOCS family proteins
[7]. We found that CD4+ T cells from patients with active
RA expressed higher levels of SOCS1, but lower levels of
SOCS3, compared with normal CD4+ T cells. SOCS1 pre-
vents activation of JAK by directly binding to JAK, and
SOCS3 inhibits the action of JAK by binding to the Src
homology phosphatase-2-binding domain of receptors
such as gp130 [40]. SOCS1 and SOCS3 are induced by
various cytokines, including IL-6 and IL-10, as mediators of
negative feedback and crosstalk inhibition [7]. Recent stud-
ies with mice lacking SOCS3 or SOCS1 revealed that
SOCS3 is a negative regulator of IL-6 signaling but not of
IL-10 signaling. Studies of conditional SOCS3-deficient
mice have shown that SOCS3 deficiency, but not SOCS1
deficiency, results in sustained activation of STAT3 in
response to IL-6 [8,41]. The analysis of SOCS3-deficient
macrophages has indicated that SOCS3 is a crucial inhib-
itor of the IL-6-induced transcriptional response [42]. How-
ever, SOCS3 is dispensable for both the negative
feedback inhibition and the immunoregulatory action of IL-
10 in macrophages [41]. On the contrary, SOCS1 was
found to directly inhibit IL-10-mediated signaling [43].
Increased SOCS1 expression in RA CD4+ T cells may
therefore be associated with both the impaired responsive-
ness to IL-10 and to IL-10-mediated STAT3 activation, and
defective SOCS3 expression may be responsible for per-
sistent STAT3 activation in response to serum IL-6.
There is a possibility that SOCS1 induction may be associ-
a t e d  w i t h  t h e  a b i l i t y  o f  C D 4 + T cells to produce IFN-γ,
because CD4+ T cells from active RA could produce high
levels of IFN-γ in the presence of IL-10, and because IFN-γ
has been known as a potent inducer of SOCS1 [32]. It is
of interest in this regard to indicate that polarized Th1 and
Th2 cells express high levels of SOCS1 and SOCS3
mRNA, respectively [44]. IL-12-induced STAT4 activation
is inhibited by SOCS3 induction in Th2 cells, whereas IL-
4-induced STAT6 signaling is diminished by SOCS1
induction in Th1 cells. SOCS1 and SOCS3 may thus have
important roles as Th1-specific and Th2-specific, mutually
exclusive, cross-talk repressors of the IL-4–STAT6 and the
IL-12–STAT4 signaling pathways, respectively. Consistent
with this notion, PB T cells from patients with allergic dis-
eases significantly express high levels of SOCS3 tran-
scripts, and the SOCS3 expression correlates well with
serum IgE levels and disease pathology [45]. Higher
SOCS1 expression with lower SOCS3 expression in PB
CD4+ T cells from RA patients, compared with healthy con-
trols, is therefore probably consistent with their systemicArthritis Research & Therapy    Vol 6 No 6    Yamana et al.
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bias towards a Th1 phenotype, as has previously been
demonstrated [46-49].
Conclusion
CD4+ T cells from active RA patients are characterized by
their resistance to IL-10 inhibition of IFN-γ production, due
to constitutive STAT3 phosphorylation and impaired IL-10-
mediated STAT3 activation. The defective STAT3 signaling
is possibly associated with SOCS1 predominance over
SOCS3. These abnormalities in active RA are thought to
be induced mainly after chronic exposure to high concen-
trations of IL-6. The limited efficacy of IL-10 treatment of RA
patients [50] may be explained in part by the unresponsive-
ness to IL-10 of inflammatory cells, including T cells. On the
contrary, the therapeutic efficacy of anti-IL-6 receptor anti-
body has been reported in RA patients [51], and one of the
effects of this therapy may be to normalize T cells through
the inhibition of IL-6-dependent STAT3 activation. More
specific therapy targeting STAT3 activation will be awaited;
for example, the induction of the SOCS3 gene, the efficacy
of which has been demonstrated in animal models [37].
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